Description
Lintuzumab is a humanized monoclonal antibody, HuM195, that targets the cell surface antigen CD33 that is expressed on the vast majority of acute myeloid leukemia (AML) cells. [225 Ac]Ac-lintuzumab clinical trials were discussed in detail in reference . Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).
Catalog No.
DHD37502
Host species
Humanized
Species reactivity
Human
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
1 mg/ml
Purity
>95% by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1-kappa
Applications
Research Grade Biosimilar
Target
Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
P20138
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
225Ac-lintuzumab, HuM195, SGN-33, SMART M195, HuM195, CAS: 166089-32-3
Note
For research use only. Not suitable for clinical or therapeutic use.
关键字: Lintuzumab;DHD37502;gp67, SIGLEC3;
武汉佰乐博生物(Biolab Reagents )作为普健生物旗下控股子品牌,专注于引进、整合全球业内高品质蛋白、抗体产品。作为法国ProteoGenix、Antibodysystem品牌亚洲区独家运营代理商。提供近2万种以蛋白、抗体为核心的生命科学试剂,旨在为生命科学科研工作者提供专业、全面、可靠的试剂产品。